Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
SelectImmune Pharma AB has filed for patent protection over a range of new agents that show surprising levels of activity in treatment of pyelonephritis. This new patent application adds to SelectImmune Pharma's expanding range of intellectual property rights in the pharmaceutical sector, specifically for treating bacterial infections.
Acute pyelonephritis or kidney infection, is a severe and common form of urinary tract infection, caused by bacteria that directly infect the kidneys. In about 30% of adults with acute pyelonephritis, bacteria invade the blood stream, causing urosepsis and without appropriate treatment, mortality is high. Acute pyelonephritis is also common in childhood, and may cause long-term problems by damaging renal tissue.
Following extensive research at Lund University into new treatment options for acute pyelonephritis, efficient new approaches have now been identified and the therapeutic effects confirmed in animal models, strengthening the commitment to develop these substances for future clinical use.
"We are delighted to make progress for this important patient group, through our molecular studies of disease determinants and the response to infection," says Catharina Svanborg, Chaiman of the board, SelectImmune Pharma.
"Selectimmune Pharma is pleased to announce a continued strengthening of its intellectual property portfolio through this new patent application for treatment of pyelonephritis,'' says Ann Gidner, CEO of SelectImmune Pharma.
For more information, please contact:
Catharina Svanborg
Chairman of the board SelectImmune Pharma AB
Phone: +46 709 42 65 49
E-mail: catharina.svanborg@med.lu.se
Ann Gidner
CEO SelectImmune Pharma AB
Phone: +46 768 17 14 14
E-mail: ann.gidner@selectImmune.com
This disclosure contains information that SelectImmune is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 01-02-2022 10:37 CET.